Review article: Should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 19, Issue 1, 2004, Pages 9-16

  Hunt, R H ^a   Bazzoli, F ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ANAMNESIS; CLINICAL TRIAL; DUODENUM INJURY; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MICROVASCULAR ISCHEMIA; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RELAPSE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STOMACH DISEASE; STOMACH LESION; STOMACH MUCOSA INJURY; TOXICITY; TREATMENT OUTCOME; ULCER HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; RECURRENCE; RISK FACTORS; WOUND HEALING;

EID: 1342289474     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
2. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 686-92.
3. Fries JF. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18(Suppl. 28): 6-10.
4. Loeb DS, Ahlquist DA, Talley NJ. Management of gastroduodenopathy associated with use of nonsteroidal anti-inflammatory drugs. Mayo Clin Proc 1992; 67: 354-64.
5. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38: 5-18.
6. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where do we stand? Am J Gastroenterol 1996; 91: 2080-6.
7. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastronterol 1997; 24: 2-17.
8. McCarthy DM. Non-steroidal anti-inflammatory drugs: reducing risks to the gastrointestinal tract. Clinical Perspectives in Gastroenterology 1999; (July/August): 219-26.
9. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis. Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8-16.
10. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? J Rheumatol 1999; 26(Suppl. 56): 31-6.
11. Geis GS, Stead H, Wallemark CB, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl 1991; 28: 11-4.
12. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
13. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
14. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001; 15: 1593-601.
15. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. J Am Med Assoc 2000; 284: 1247-55.
16. Sorensen MT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with the use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218-24.
17. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-6.
18. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.
19. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long-term aspirin use: a meta-analysis. Br Med J 2000; 321: 1183-7.
20. Yeomans N, Hawkey C, Lanas A, Naesdal J, Talley N, Thomson A. Prevalence of gastric and duodenal ulcers during treatment with 'low dose' aspirin. Gastroenterology 2002; 122: A-87(Abstract 701).
21. Stack WA, Atherton JC, Hawkey GM, et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 497-506.
22. Go MF. Review article, natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16(Suppl. 1): 3-15.
23. Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114: 245-55.
24. Heresbach D, Raoul JL, Bretagne JF, et al. Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy. Gut 1992; 33: 1608-16.
25. Santucci L, Fiorucci S, Patoia L, DiMatteo FM, Brunori PM, Morelli A. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Dig Dis Sci 1995; 40: 2074-80.
26. Hui E, Sung J, Leung V, et al. Effects of age, Helicobacter pylori, and NSAID usage on the upper gastrointestinal tract. J Am Geriatr Soc 1996; 44: 1010-2(Letter).
27. Chan FKL, Sung JJY, Chung SCS, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent ulcers. Lancet 1997; 350: 975-9.
28. Graham DY, Lidsky MD, Cox AM. et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter infection. Gastroenterology 1991; 100: 1653-7.
29. Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury. the role of Helicobacter pylori. Gastroenterology 1992; 102: 1899-905.
30. Lanza FL, Evans DG, Graham DY. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. Am J Gastroenterol 1991; 86: 735-7.
31. Goggin PM, Collins DA, Jazrawi RP, et al. Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 1993; 34: 1677-80.
32. Voutilainen M, Mantynen T, Farkkila M, Juhola M, Sipponen P. Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. Scand J Gastroenterol 2001; 36: 817-21.
33. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999; 116: 1305-9.
34. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
35. Cryer B, Cung AD, Kelly KC, Weideman RA. Risk of diverticular bleeding with NSAIDs and low-dose aspirin. Gastroenterology 2002; 118: A249(Abstract 698).
36. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R, Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-86.
37. Bazzoli F, De Luca L, Graham DY. Helicobacter pylori infection and the use of NSAIDs. Best Pract Res Clin Gastroenterol 2001; 15: 775-85.
38. Malfertheiner P, and the European Helicobacter pylori Study Group. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002; 16: 167-80.
39. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
40. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51: 329-35.
41. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73.
42. Campbell DR, Haber MM, Sheldon E, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing non-steroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002; 97: 2208-14.
43. van Herwaarden MA, Samsom M, van Nispen CH, Mulder PG, Smout AJ. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13: 731-40.
44. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169-75.
45. Chan FK, Sung JJ, Suen R, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998; 12: 1201-5.
46. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-8.